Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
KalVista Pharmaceuticals ( (KALV) ) just unveiled an announcement.
KalVista Pharmaceuticals, Inc. has appointed Brian Piekos as the new Chief Financial Officer. With over 25 years in the biopharmaceutical industry, Piekos is equipped with a vast experience, having served in similar roles at Elicio Therapeutics, Gemini Therapeutics, and AMAG Pharmaceuticals. His track record in financial and strategic planning is expected to be pivotal as KalVista prepares for the commercial launch of sebetralstat, a novel therapy for hereditary angioedema. His appointment includes a comprehensive compensation package, including a base salary, bonus target, and stock options, alongside severance benefits that align with his new role.
See more insights into KALV stock on TipRanks’ Stock Analysis page.
